Actively Recruiting

Phase 4
Age: 18Years - 60Years
All Genders
NCT07432815

Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant

Led by Cairo University · Updated on 2026-05-05

40

Participants Needed

1

Research Sites

47 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This randomized controlled trial aims to compare the efficacy of methotrexate (MTX) monotherapy versus combined methotrexate and selective serotonin reuptake inhibitor (SSRI) therapy in patients with psoriasis and comorbid depression and/or anxiety. Participants will be randomly assigned to two groups: one receiving MTX alone and the other receiving MTX plus escitalopram. Clinical outcomes will be evaluated over a 6-month period, including psoriasis severity using the Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA), quality of life using the Dermatology Life Quality Index (DLQI), and psychological status using the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A). The study will assess whether combination therapy provides superior clinical and psychological outcomes.

CONDITIONS

Official Title

Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant

Who Can Participate

Age: 18Years - 60Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged >18 and <60 years
  • Moderate to severe psoriasis (PASI �3e�3d10 or BSA �3e�3d10%)
  • Moderate to severe depression (BDI �3e�3d20 or HAM-D �3e�3d17) and/or moderate to severe anxiety (BAI �3e�3d16 or HAM-A �3e�3d25)
Not Eligible

You will not qualify if you...

  • Current substance abuse
  • Systemic psoriasis treatment within the past 3 months
  • Pregnancy or breastfeeding
  • Hypersensitivity to methotrexate or escitalopram
  • Erythrodermic or pustular psoriasis
  • Contraindications to methotrexate (e.g., hepatic disease or malignancy)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Kasralainy

Cairo, Cairo Governorate, Egypt, 11562

Actively Recruiting

Loading map...

Research Team

N

Naglaa Mohsen, Resident

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here